Evolent Health (NYSE: EVH) president sells, holds 655,133 shares

Rhea-AI Filing Summary

Evolent Health, Inc. (EVH) reported that its President, Daniel Joseph McCarthy, sold 65,892 shares of Class A Common Stock on August 26, 2026 at $5.00 per share in an open-market or private transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on May 22, 2026. After this transaction, McCarthy directly holds 655,133 shares, which include previously granted restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 65,892 shares

Net Sell 1 txn

Insider McCarthy Daniel Joseph

Role PRESIDENT

Sold 65,892 shs ($329K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock F1, F2	65,892	$5.00	$329K

Holdings After Transaction: Class A Common Stock — 655,133 shares (Direct)

Footnotes (2)

1. F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026.
2. F2. Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

Key Figures

Shares sold: 65,892 shares of Class A Common Stock Sale price per share: $5.00 per share Shares held after transaction: 655,133 shares +1 more

4 metrics

Shares sold 65,892 shares of Class A Common Stock Sale on August 26, 2026 reported on Form 4

Sale price per share $5.00 per share Price for the 65,892 shares sold on August 26, 2026

Shares held after transaction 655,133 shares Direct holdings after the reported sale, including restricted stock units

Net shares sold 65,892 shares Net-sell direction across all reported transactions in this Form 4

Key Terms

Rule 10b5-1 trading plan, restricted stock units, Class A Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported ... were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes restricted stock units granted under awards reported on Table 1"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

What insider transaction did EVH report for Daniel Joseph McCarthy?

Evolent Health, Inc. reported that President Daniel Joseph McCarthy sold 65,892 shares of Class A Common Stock on August 26, 2026 at $5.00 per share in a sale classified as an open-market or private transaction.

How many EVH shares did Daniel Joseph McCarthy sell and at what price?

Daniel Joseph McCarthy sold 65,892 EVH shares of Class A Common Stock at a price of $5.00 per share, according to the Form 4 insider transaction report.

How many EVH shares does Daniel Joseph McCarthy hold after this Form 4 transaction?

Following the reported sale, Daniel Joseph McCarthy directly holds 655,133 shares of Evolent Health, Inc. Class A Common Stock, which the filing states includes restricted stock units from prior equity awards.

Was the EVH insider sale by Daniel Joseph McCarthy under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Daniel Joseph McCarthy on May 22, 2026, indicating the trades were pre-arranged under that plan.

What role does Daniel Joseph McCarthy hold at Evolent Health, Inc. (EVH)?

Daniel Joseph McCarthy is identified in the filing as President of Evolent Health, Inc., and he is the reporting person for the disclosed Form 4 insider stock sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/28/2026 - 04:18 PM Accepted by SEC EDGAR 08/28/2026 - 04:17 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCarthy Daniel Joseph

(Last) (First) (Middle)

C/O EVOLENT HEALTH, INC.

1812 N. MOORE ST., STE. 1705

(Street)

ARLINGTON VIRGINIA 22209

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evolent Health, Inc. [ EVH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/26/2026		S(1)		65,892	D	$5	655,133(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2026.

2. Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.

Remarks:

	/s/ Jonathan Weinberg, Attorney-in-fact	08/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)